Genetic and epigenetic alterations in breast cancer: What are the perspectives for clinical practice?

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 4, 2008, Pages 565-575

  Fucito, Alfredo ^a   Lucchetti, Chiara ^a,b   Giordano, Antonio ^a,b   Romano, Gaetano ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Breast cancer; Epigenetic; Genetic; Genomic medicine; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; TAMOXIFEN;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOLOGY; DISEASE COURSE; EPIGENETICS; HUMAN; MOLECULAR BIOLOGY; MUTATION; PATHOGENESIS; QUALITY OF LIFE; SHORT SURVEY; SINGLE DRUG DOSE; SURVIVAL RATE;

BREAST NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; HUMANS; MODELS, BIOLOGICAL;

EID: 39649113846     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.10.018     Document Type: Short Survey

References (108)

1. Albrektsen G., Heuch I., Thoresen S., and Kvale G. Clinical stage of breast cancer by parity, age at birth, and time since birth: A progressive effect of pregnancy hormones?. Cancer Epidemiol. Biomarkers Prev. 13 1 (2006) 65-69
2. Andrieu N., Goldgar D.E., Easton D.F., Rookus M., Brohet R., Antoniou A.C., et al. Pregnancies, breast-feeding, and breast cancer rosk in the international BRCA1/2 carrier cohort study (BCCS). J. Natl. Cancer Inst. 98 8 (2006) 535-544
3. Arce C., Segura-Pacheco B., Perez-Cardenas E., Taia-Chaveb L., Candelaria M., and Duennas-Gonzalez A. Hydralazine target: From blood to the epigenome. J. Transl. Med. 4 (2006) 10
4. Arsian A.A., Zaleniuch-Jacquotte A., Lukanova A., Afanasveva Y., Katz J., Levitz M., et al. Effects of parity on pregnancy hormonal profiles across ethnic groups with a diverse incidence of breast cancer. Cancer Epidemiol. Biomarkers Prev. 15 11 (2006) 2123-2130
5. Bannister A.J., and Kouzarides T. Reversing histone methylation. Nature 436 7054 (2005) 1103-1106
6. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stm cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 7120 (2006) 756-760
7. Baxter C.S., and Byvoet P. Intercalating agents as probes of the spatial relationship between chromatin components. Biochem. Biophys. Res. Commun. 63 1 (1975) 286-291
8. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activites of histone deactylase inhibitors. Nat. Rev. Drug Discov. 5 9 (2006) 769-784
9. Bradbury A.R., and Olopade O.I. Genetic susceptibility to breast cancer. Rev. Endocr. Metab. Disord. 8 3 (2007) 255-267
10. Braun S., Vogl F.D., Janni W., Marth C., Schlimok G., and Pantel K. Evaluation of bone marrow in breast cancer patients: Prediction of clinical outcome and response to therapy. Breast 12 6 (2003) 397-404
11. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353 8 (2005) 793-802
12. Brueckner B., Boy R.G., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferase. Cancer Res. 65 14 (2005) 6305-6311
13. Burstein H.J., Parker L.M., and Savoie J. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res. Treat. 76 Suppl. 1 (2002) S115 [abstract 446]
14. Byvoet P., Shepherd G.R., Hardin J.M., and Noland B.J. The distribution and turnover of labeled methyl groups in histone fractions of cultured mammalian cells. Arch. Biochem. Biophys. 148 2 (1972) 558-567
15. Callinan P.A., and Feinberg A.P. The emerging science of epigenomics. Hum. Mol. Genet. 15 Special issue 1 (2006) R95-R101
16. Cardillo M.R., Yap E., and Castagna G. Molecular genetic analysis of TGF beta1 in breast cancer. J. Clin. Cancer Res. 16 1 (1997) 57-63
17. Cascio S., Bartella V., Garofalo C., Russo A., Giordano A., and Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J. Biol. Chem. 282 6 (2007) 3498-3506
18. Chabner B.A., and Roberts Jr. T.G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 5 (2005) 65-72
19. Cheema B., Gaul C.A., Lane K., and Fiatarone Singh M.A. Progressive resistance training in beast cancer: A systematic review of clinical trials. Breast Cancer Res. Treat. (2007) [epub ahead of print]
20. Chen W.Y., and Colditz G.A. Risk factors and hormone-receptor status: Epidemiology, risk-prediction models and treatment implications for breast cancer. Nat. Clin. Pract. Oncol. 4 7 (2007) 415-423
21. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356 1 (2007) 11-20
22. Chia S.K.L., Speers C., Kang D., Yachlova Y., Malfair-Taylor S., et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc. Am. Soc. Clin. Oncol. 22 6 (2003) 22 [abstract]
23. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., et al. A phase I-II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30 Suppl. 16 (2003) 117-124
24. Czermin B., Melfi R., McCabe D., Seitz V., Imhof A., and Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that mraks chromosomal polycomb sites. Cell 111 2 (2002) 185-196
25. Dukers D.F., van Galen J.C., Giroth C., Jansen P., Sewalt R.G., Otte A.P., et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am. J. Pathol. 164 7 (2004) 873-881
26. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63 22 (2003) 7563-7570
27. Feinberg A.P. Methylation meets genomics. Nat. Genet. 27 1 (2001) 9-10
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
29. Foulkes W.D., Metcalfe K., Sun P., Hanna W.M., Lynch H.T., Ghadirian P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin. Cancer Res. 10 (2004) 2029-2034
30. Gan D.D., Macaluso M., Cinti C., Khalili K., and Giordano A. How does a normal cell become a cancer cell?. J. Exp. Clin. Cancer Res. 22 4 (2003) 509-516
31. Giordano A., Fucito A., Romano G., and Marino I.R. Carcinogenesis and environment: The cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front. Biosci. 12 (2007) 3475-3482
32. Giordano A., Rossi A., Romano G., and Bagella L. Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy. J. Cell. Physiol. 213 2 (2007) 403-406
33. Glinsky G.V., Berezovska O., and Glinskii A.B. Micorarray analysis reveals a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115 6 (2005) 1503-1521
34. Gordon M.S., Margolin K., Talpaz M., Sledge Jr. G.W., Holmgren E., Benjamin R., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19 (2001) 840-843
35. Gumus M., Yumuk P.F., Salepci T., Allustaoglu M., Dane F., Ekenel M., et al. HPV DNA frequency and subset in human breast cancer patients' normal and tumoral tissue samples. J. Exp. Clin. Cancer Res. 25 4 (2006) 515-521
36. Guttmacher A.E., and Collins F.S. Genomic medicine-A primer. N. Engl. J. Med. 347 19 (2002) 1512-1520
37. Ha M., Mabuchi K., Sigurdson A.J., Freedman D.M., Linet M.S., Doody M.M., et al. Smocking cigarettes before first childbirth and risk of breast cancer. Am. J. Epidemiol. 166 1 (2007) 55-61
38. Herbst R.S., and Lippman S.M. Molecular signatures of lung cancer-Toward personalized therapy. N. Engl. J. Med. 356 1 (2007) 76-78
39. Herrera J.E., Schiltz R.L., and Bustin M. The accessibility of histone H3 tails in chromatin modulates their acetylation by P300/CBP-associated factor. J. Biol. Chem. 275 17 (2000) 12994-12999
40. Herrera J.E., West K.L., Schiltz R.L., Nakatani Y., and Bustin M. Histone H1 is a specific repressor of core histone acetylation in chromatin. Mol. Cell. Biol. 20 2 (2000) 523-529
41. Huh J.I., Calvo A., Stafford J., Cheung M., Kaman R., Philip D., et al. Inhibitors of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24 (2005) 790-800
42. Hynes N.E., and Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
43. Imay K., and Tanaka A. Comparing antibody and small molecule therapy for cancer. Nat. Rev. Cancer 6 (2006) 714-727
44. Jemal A., Siegel R., Want E., Murray T., Xu J., Snigal C., et al. Cancer statistics. CA Cancer J. Clin. 56 2 (2006) 106-130
45. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
46. Karakosta A., Golias C., Charalabopoulos A., Peschos D., Batistatou A., and Charalabopoulos K. Genetic model of human cancer as a multistep process, paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukemia. J. Exp. Clin. Cancer Res. 24 4 (2005) 505-514
47. Kass S.U., Pruss D., and Wolffe A.P. How does DNA methylation repress transcription?. Trends Genet. 13 11 (1997) 444-449
48. Kawaguchi Y., Kono K., Mimura K., Mitsui F., Sugai H., Akaike H., et al. Targeting EGFR and HER-2 with cetuximab and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br. J. Cancer (2007) [epub ahead of print]
49. Kim K.J., Li B., Winer J., Armanini M., Gillet N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362 (1993) 841-844
50. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 2 (2006) 265-275
51. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 100 20 (2003) 11606-11611
52. Kuhl C.K. High-risk screening: Multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene). J. Exp. Clin. Cancer Res. 21 Suppl. 3 (2002) 103-106
53. Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., and Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev. 16 22 (2002) 2893-2905
54. Lawson J.S., Gunzburg W.H., and Whittaker N.J. Viruses and human breast cancer. Future Microbiol. 1 (2006) 33-51
55. Lee D.Y., Hayes J.J., Pruss D., and Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72 1 (1993) 73-84
56. Litt M.D., Simpson M., Recillas-Targa F., Prioleau M.N., and Felsenfeld G. Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J. 20 9 (2001) 2224-2235
57. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356 3 (2007) 217-226
58. Luger K. Dynamic nucleosomes. Chromosome Res. 14 (2006) 5-16
59. Macaluso M., Cinti C., Russo G., Russo A., and Giordano A. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-α in breast cancer. Oncogene 22 23 (2003) 3511-3517
60. Macaluso M., Montanari M., and Giordano A. Rb family proteins as modulators of gene expression and new aspects regarding the interactions with chromatin remodeling enzymes. Oncogene 25 38 (2006) 5263-5267
61. Macaluso M., Montanari M., Noto P.B., Gregorio V., Bronner C., and Giordano A. Epigenetic modulation of estrogen receptor-α by pRb family proteins: A novel mechanism in breast cancer. Cancer Res. 67 16 (2007) 7731-7737
62. Macaluso M., Paggi M., and Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 22 42 (2003) 6472-6478
63. Margolin K., Gordon M.S., Holigren E., Gandreault J., Novotny W., Fyfe G., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chremotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J. Clin. Oncol. 19 (2001) 851-856
64. Marvin K.W., Yau P., and Bradbury E.M. Isolation and characterization of acetylated histones H3 and H4 and their assembly into nucleosomes. J. Biol. Chem. 265 32 (1990) 19839-19847
65. Maskarinec G., Zhang Y., Takata Y., Pagano I., Shumav D.M., Goodman M.T., et al. Trends of breast cancer incidence and risk factor prevalence over 25 years. Breast Cancer Res. Treat. 98 1 (2006) 45-55
66. Menes T.S., Ozao J., and Kim U. Breast cancer and ethnicity: Strong association between reproductive risk factors and estrogen receptor status in Asian patients-A retrospective study. Breast J. 13 4 (2007) 352-358
67. Miller K.D. E2100: A phase III trial of paclitaxel versus paclitael/bevacizumab for metastatic breast cancer. Clin. Breast Cancer 3 (2003) 421-422
68. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Senim. Oncol. 42 3 Suppl. 2 (2005) S9-S16
69. Moss T.J., and Wallrath L.L. Connections between epigenetic gene silencing and human disease. Mutat. Res. 618 1/2 (2007) 163-174
70. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carrol D., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412 6845 (2001) 561-565
71. Paik W.K., and Kim S. Enzymatic demethylation of calf thymus histones. Biochem. Biophys. Res. Commun. 51 3 (1973) 781-788
72. Park Y.J., and Luger K. Structure and function of nucleosome assembly proteins. Biochem. Cell. Biol. 84 4 (2006) 549-558
73. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 6937 (2003) 302-305
74. Pasini D., Bracken A.P., and Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 3 4 (2004) 396-400
75. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5 6 (2003) 481-488
76. Radice P. Mutations of BRCA genes in hereditary breast and ovarian cancers. J. Exp. Clin. Cancer Res. 21 Suppl. 3 (2002) 9-12
77. Rennert G., Bisland-Naggan S., Barnett-Griness O., Bar-Joseph N., Zhang S., Rennert H.S., et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357 2 (2007) 119-123
78. Rice J.C., and Allis C.D. Histone methylation versus histone acetylation: New insights into epigenetic regulation. Curr. Opin. Cell. Biol. 13 3 (2001) 263-273
79. Romano G. The complex biology of the receptor for the insulin-like growth factor-1. Drug News Perspect. 16 8 (2003) 525-531
80. Romano G. The role of adult stem cells in carcinogenesis. Drug News Perspect. 18 9 (2005) 555-559
81. Romano G., Micheli P., Pacilio C., and Giordano A. Latest development in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18 1 (2000) 19-39
82. Russo A., Calo V., Agnese V., Bruno I., Corsale S., Augello C., et al. BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): A mutational analyses. Breast Cancer Res. Treat. (2007) [epub ahead of print]
83. Schotta G., Lachner M., Sarma K., Ebert A., Sengupta R., Reader G., et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18 11 (2004) 1251-1262
84. Shema L., Ore L., Ben-Shakar M., Hai M., and Linn S. The association between breastfeeding and breast cancer occurrence among Israeli Jewish women: A case control study. J. Cancer Res, Oncol. 133 8 (2007) 539-546
85. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119 7 (2004) 941-953
86. Siamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu proto-oncogene. Science 235 (1987) 177-182
87. Siamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Use of chemotherapy plus a monocloncal antibody against HER2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344 (1989) 783-792
88. Sigalotti L., Fratta E., Coral S., Cortini E., Covre A., Nicolay H.J.M., et al. Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. J. Cell. Physiol. 212 2 (2007) 330-344
89. Skiniotis G., Moazed D., and Waltz T. Acetylated histone tail peptides induce structural rearrangements in the RSC chromatin remodeling complex. J. Biol. Chem. 282 29 (2007) 20804-20808
90. Smith M.C.P., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64 23 (2004) 8604-8612
91. Sparmann A., and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6 11 (2006) 846-856
92. Stallcup M.R. Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20 24 (2001) 3014-3020
93. Stewart M.D., Li J., and Wong J. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol. Cell. Biol. 25 7 (2005) 2525-2538
94. Valk-Lingbeek M.E., Bruggeman S.W.M., and van Louizen M. Stem cells and cancer: The polycomb connection. Cell 118 4 (2004) 409-418
95. Varmus H. Getting ready for gene-based medicine. N. Engl. J. Med. 347 19 (2002) 1526-1527
96. Villar-Garea A., Fraga M.F., Espada J., and Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63 16 (2003) 4984-4989
97. Vogel V.G., and Taioli E. Have we found the ultimate risk factor for breast cancer?. J. Clin. Oncol. 24 12 (2006) 1791-1794
98. Wade P.A., Pruss D., and Wolffe A.P. Histone acetylation: Chromatin in action. Trends Biochem. Sci. 22 4 (1997) 128-132
99. Walker I.O. Differential dissociation of histone tails from core chromatin. Biochemistry 23 23 (1984) 5622-5628
100. Walsh T., and King M.C. Ten genes for inherited breast cancer. Cancer Cell 11 2 (2007) 103-105
101. Wang X., Moore S.C., Laszckzak M., and Ausio J. Acetylation increases the alpha-helical content of the histone tails of the nucleosome. J. Biol. Chem. 275 45 (2000) 35013-35020
102. Welcsh P.L., Owens K.N., and King M.C. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 16 2 (2000) 69-74
103. Wicha M.S., Lin S., and Dontu G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res. 66 4 (2006) 1883-1890
104. Widakowich C., de Azambula E., Gil T., Dinh P., Awada A., and Piccart-Gebhart M. Molecular targeted therapies in breast cancer: Where are we now?. Int. J. Biochem. Cell. Biol. 39 7-8 (2007) 1375-1387
105. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26 37 (2007) 5541-5552
106. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 7092 (2006) 475-482
107. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 5 1 (2006) 37-50
108. Zembrano P., Segura-Pacheco B., Perez-Cardenaz E., Cetina L., Revilla-Vasquez A., Taia-Chavez L., et al. A phase I study of hydralazine to demethylate and reactvate the expression of tumor suppressor genes. BMC Cancer 5 1 (2005) 44